Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients
Mediterr J Hematol Infect Dis
.
2022 Jul 1;14(1):e2022056.
doi: 10.4084/MJHID.2022.056.
eCollection 2022.
Authors
Nicola Sgherza
#
1
,
Stefania Zucano
#
2
,
Angelantonio Vitucci
1
,
Antonio Palma
1
,
Francesco Tarantini
2
,
Daniela Campanale
1
,
Luigi Vimercati
3
,
Angela Maria Vittoria Larocca
4
,
Domenico Visceglie
5
,
Amalia Acquafredda
5
,
Angelo Ostuni
6
,
Daniela Di Gennaro
2
,
Carmen Vitucci
2
,
Silvio Tafuri
7
,
Pellegrino Musto
1
2
Affiliations
1
Hematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy.
2
Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari, Italy.
3
Interdisciplinary Department of Medicine, "Aldo Moro" University School of Medicine, Occupational Medicine Unit, AOUC Policlinico, Bari, Italy.
4
Hygiene Unit, AOUC, Policlinico Bari, Bari, Italy.
5
Immuno-hematology and Transfusion Medicine Service, ASL and "Di Venere" Hospital, Bari, Italy.
6
Immunohematology and Transfusion Medicine Service, AOUC Policlinico, Bari, Italy.
7
Department of Biomedical Science and Human Oncology, "Aldo Moro" University School of Medicine, Bari, Italy.
#
Contributed equally.
PMID:
35865398
PMCID:
PMC9266603
DOI:
10.4084/MJHID.2022.056
No abstract available
Keywords:
Anti-SARS-CoV-2 vaccine; Serological response; Transfusion-dependent thalassemia.